» Articles » PMID: 28388720

New Uses of AbobotulinumtoxinA in Aesthetics

Overview
Journal Aesthet Surg J
Specialty General Surgery
Date 2017 Apr 8
PMID 28388720
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

BotulinumtoxinA (BoNT-A) is now widely established for the main approved indication of reducing glabellar lines, and is also widely used off-label to improve the appearance of wrinkles and lines in other parts of the face. The number of aesthetic procedures continues to increase as the patient population becomes more diverse, in particular with increasing numbers of people of color and men. Further developments in treatment may continue to expand the audience for BoNT-A by making procedures more comfortable and by delivering a more natural, less static appearance. These may be achieved through use of combinations of BoNT-A with other aesthetic procedures, tailoring the dose of toxin to the patient's muscle mass or by using novel injection and application techniques. Beyond amelioration of facial lines, encouraging results have been seen with the use of BoNT-A to improve the appearance of hypertrophic and keloid scars and even to prevent them. Studies have been conducted with scars in various parts of the body and further research is ongoing. Dermatological and other medical uses for BoNT-A are also active areas of research. Injections of BoNT-A have been shown to reduce signs and symptoms of acne, rosacea, and psoriasis, to reduce neuromuscular pain, and to bring about significant improvements in a number of rare diseases that are caused or exacerbated by hyperhidrosis. This paper reviews these new uses for BoNT-A, looking at the rationale for their use and discussing the results of published case studies and clinical trials. These areas have shown great promise to date, but more and larger clinical studies will be required before these treatments become a clinical reality. To this end details are also provided of clinical trials currently listed in the main clinical trials database to highlight research areas of particular interest.

Citing Articles

Botulinum Toxin in Aesthetic Medicine: A Bibliometric Analysis of Research Trends and Methodological Quality of the Top 100 Cited Publications.

Wong Z, Damavandi P, Richards M, Danpanichkul P, Adegboye O, Faderani R Aesthet Surg J Open Forum. 2025; 7:ojae131.

PMID: 39974503 PMC: 11836436. DOI: 10.1093/asjof/ojae131.


Prospects for Use of Botulinum Toxin Type A for Prevention of Hypertrophic and Keloid Scars after Surgeries.

Korableva N, Romanenkov N, Kremlev D, Nekrasov A, Miroshnichenko M, Arbekov P Indian J Plast Surg. 2024; 57(6):421-431.

PMID: 39734381 PMC: 11679196. DOI: 10.1055/s-0044-1787175.


An Ultrasonographic Analysis of the Deep Inferior Tendon in the Masseter Muscle: Implications for Botulinum Toxin Injections.

Shi J, Li C, Zhou J, Guo X, Li G, You M Toxins (Basel). 2024; 16(9).

PMID: 39330849 PMC: 11436078. DOI: 10.3390/toxins16090391.


Embracing the Versatility of Botulinum Neurotoxins in Conventional and New Therapeutic Applications.

Rasetti-Escargueil C, Palea S Toxins (Basel). 2024; 16(6).

PMID: 38922155 PMC: 11209287. DOI: 10.3390/toxins16060261.


Microdroplet Botulinum Toxin: A Review.

Kandhari R, Kaur I, Gupta J, Al-Niaimi F J Cutan Aesthet Surg. 2022; 15(2):101-107.

PMID: 35965899 PMC: 9364467. DOI: 10.4103/JCAS.JCAS_162_21.


References
1.
Shah A . Use of intradermal botulinum toxin to reduce sebum production and facial pore size. J Drugs Dermatol. 2008; 7(9):847-50. View

2.
Glogau R, Blitzer A, Brandt F, Kane M, Monheit G, Waugh J . Results of a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of a botulinum toxin type A topical gel for the treatment of moderate-to-severe lateral canthal lines. J Drugs Dermatol. 2011; 11(1):38-45. View

3.
Mole B . [Scratched faces: treatment of dynamic facial wrinkles through the simultaneous combined use of botulinium toxin A and hyaluronic acid]. Ann Chir Plast Esthet. 2012; 57(3):194-201. DOI: 10.1016/j.anplas.2012.02.001. View

4.
Chang C, Wallace C, Hsiao Y, Chang C, Chen P . Botulinum toxin to improve results in cleft lip repair: a double-blinded, randomized, vehicle-controlled clinical trial. PLoS One. 2014; 9(12):e115690. PMC: 4277415. DOI: 10.1371/journal.pone.0115690. View

5.
Huang C, Akaishi S, Hyakusoku H, Ogawa R . Are keloid and hypertrophic scar different forms of the same disorder? A fibroproliferative skin disorder hypothesis based on keloid findings. Int Wound J. 2012; 11(5):517-22. PMC: 7950391. DOI: 10.1111/j.1742-481X.2012.01118.x. View